- Home
- IGC vs BNR Comparison
IGC vs BNR Comparison
Compare IGC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- BNR
- Stock Information
- Founded
- IGC 2005
- BNR 2014
- Country
- IGC United States
- BNR China
- Employees
- IGC N/A
- BNR N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- IGC Health Care
- BNR Health Care
- Exchange
- IGC Nasdaq
- BNR Nasdaq
- Market Cap
- IGC 39.8M
- BNR 38.3M
- IPO Year
- IGC N/A
- BNR 2020
- Fundamental
- Price
- IGC $0.41
- BNR $8.27
- Analyst Decision
- IGC Strong Buy
- BNR
- Analyst Count
- IGC 2
- BNR 0
- Target Price
- IGC $4.00
- BNR N/A
- AVG Volume (30 Days)
- IGC 1.3M
- BNR 38.7K
- Earning Date
- IGC 11-11-2025
- BNR 09-08-2025
- Dividend Yield
- IGC N/A
- BNR N/A
- EPS Growth
- IGC N/A
- BNR N/A
- EPS
- IGC N/A
- BNR N/A
- Revenue
- IGC $1,327,000.00
- BNR $74,862,782.00
- Revenue This Year
- IGC $15.26
- BNR $136.32
- Revenue Next Year
- IGC $3.41
- BNR N/A
- P/E Ratio
- IGC N/A
- BNR N/A
- Revenue Growth
- IGC 24.95
- BNR 5.20
- 52 Week Low
- IGC $0.25
- BNR $2.18
- 52 Week High
- IGC $0.50
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- IGC 51.81
- BNR 51.01
- Support Level
- IGC $0.38
- BNR $8.30
- Resistance Level
- IGC $0.44
- BNR $9.55
- Average True Range (ATR)
- IGC 0.03
- BNR 0.70
- MACD
- IGC -0.00
- BNR -0.15
- Stochastic Oscillator
- IGC 32.33
- BNR 24.68
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.